2023年6月13日

HepQuant宣布增加行政领导团队来推动商业化凯利r·皮特博士,首席运营官;嘉莉Mulherin, MBA首席商务官;Shailesh Chavan医学博士,首席医疗官;Paige Nardi, MBA市场副总裁访问丹佛——(业务线)——#医疗——HepQuant LLC改变肝脏疾病的管理领导者,宣布主要增加了它的行政领导团队。四个经验丰富的高管加入HepQuant打造公司的领导团队和完成准备推出其定量肝功能试验。HepQuant使医疗服务提供者能够更有效地管理肝脏疾病患者,来识别人肝脏疾病的风险。公司开发非侵入式的、定量的产品直接测量肝脏健康准确风险分层患者并告知治疗决策。皮特博士加入HepQuant拥有超过20年的业务,研发和运营领导经验在生物技术、生物制药和医疗诊断。他带给HepQuant核心优势操作监督生产和临床实验室、合并和收购、合同谈判、知识产权管理、损益报告,提高利润率,战略规划和长期预算问责制。皮特博士最近担任业务高级副总裁C2N诊断,诊断公司专注于生物学标志物的诊断、病程和治疗人类大脑疾病的监测。 Prior to C2N Diagnostics, Dr. Pitts was the President and Chief Scientific Officer for Colorado Operations at Corgenix. Carrie Mulherin, MBA joined the Company in May as Chief Commercial Officer and will build and lead the sales and marketing organization. She is a diagnostics industry executive with deep experience in strategic marketing, cross-functional team management, commercialization and reimbursement strategy. Most recently, she was VP of Life Sciences at Atonarp, a Tokyo-based start-up developing mass spectrometry and optical spectroscopy platforms. Prior to Atonarp, Carrie served as Chief Marketing Officer at LightDeck Diagnostics, a point-of-care platform technology company with products for the emergency department and critical care, clinics, veterinary and environmental testing. Shailesh Chavan, MD joined HepQuant in May as Chief Medical Officer. He is a physician-executive with more than 20 years’ experience in the pharma, biotech and clinical research organization. His areas of expertise include drug and device development in immunology, oncology, neurology and transplant medicine. He was most recently Vice President Clinical Development and Clinical Operations at Veloxis Pharmaceuticals, with responsibility for management of all clinical programs. Prior to Veloxis, Dr. Chavan served as Senior Medical Director, Clinical Medicine at Takeda Pharma and Global Clinical Development Lead for Transplant Programs at Shire Pharma (prior to acquisition by Takeda). Paige Nardi, MBA joined the Company in June. She has a proven track record of developing and implementing strategies and programs in the pharmaceutical and molecular diagnostics market segments. Paige has expertise in pharmacy benefits, medical management and policy, coding and reimbursement, contracting, and pre-authorization/appeals of complex claims. Most recently, Paige served as Executive Director, Market Access for Scipher Medicine, a precision immunology company. Prior to Scipher, she was Vice President of Sales at Envolve Pharmacy Solutions and Director of Managed Care at Biodesix. “This team understands the medicine and business aspects of our industry to take HepQuant from a development-stage company to a commercial enterprise,” said Greg Everson, MD, Founder and CEO. “They each have expertise in their respective domains and have built and developed complex operations, sales and marketing, medical affairs, and reimbursement organizations. These are exactly the skill sets HepQuant needs to build and scale to make the Company a commercial success.” About HepQuant HepQuant is developing non-invasive diagnostic products that directly measure liver function to enable healthcare providers to treat people with liver diseases more effectively. Liver function is the key indicator of liver health. Knowing where a patient falls on the disease spectrum informs treatment decisions for that individual. HepQuant is a privately held diagnostics company based in Denver, Colorado. Learn more at www.HepQuant.com . HepQuant products are investigational combination drug and in vitro diagnostic devices and have not been evaluated or reviewed by the US Food and Drug Administration for commercial sale. They are currently available for investigational use via the FDA guidelines for investigational device exemptions (IDEs). Contacts